ctDNA is not a simple positive/negative binary test. Like PSA in prostate cancer, the quantitative level of ctDNA correlates with patient outcomes. Higher levels indicate a worse prognosis and a faster time to relapse, allowing for more nuanced risk stratification beyond a simple presence or absence of the biomarker.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

Circulating tumor DNA is a powerful tool for detecting systemic minimal residual disease but is not sensitive enough for local, non-muscle invasive recurrences. This limitation means traditional surveillance like cystoscopy remains indispensable, as a negative ctDNA test can provide a false sense of security about local control.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

Professor Powles highlights a critical limitation of ctDNA in bladder cancer management. While excellent for assessing systemic risk, ctDNA may remain negative during a local, non-muscle invasive relapse (e.g., T1 cancer). This necessitates continued local surveillance like cystoscopy, even in ctDNA-negative patients pursuing bladder-sparing approaches.

Experts find a positive circulating tumor DNA (ctDNA) test more useful for informing a decision to start adjuvant therapy. A negative result is considered less helpful and doesn't provide the same level of reassurance or definitively rule out treatment, as the pivotal clinical trial was designed to address the ctDNA-positive scenario.

While promising, current ctDNA technology is not robust enough to justify stopping effective neoadjuvant systemic therapy in bladder cancer, even if a patient becomes ctDNA negative. Experts argue against using it to de-escalate treatment outside of a clinical trial due to the risk of undertreating a lethal disease.

Beyond a simple positive/negative result, the quantitative level of ctDNA is highly prognostic in bladder cancer. Similar to PSA in prostate cancer, higher ctDNA levels correlate with a significantly worse prognosis, offering a more nuanced risk assessment tool than a binary test.

In neoadjuvant breast cancer treatment, patients with residual cancer post-therapy remain at high risk of recurrence (10-20%) even if their ctDNA tests are negative. This finding suggests that the physical presence of residual disease is a critical factor, and ctDNA status alone cannot justify forgoing additional adjuvant therapy in this cohort.